Results 211 to 220 of about 37,412,989 (241)
Some of the next articles are maybe not open access.
Clearance Constants in Physiologically Based Pharmacokinetic Models
Journal of Pharmaceutical Sciences, 1979The intrinsic clearance of an organ is usually approximated by the apparent clearance from that organ in the development of a physiologically based pharmacokinetic model. In this study, the exact relationship between the two clearances was derived and analyzed.
H S, Chen, J F, Gross
openaire +2 more sources
Development of a physiologically based pharmacokinetic model for chloroform
Toxicology and Applied Pharmacology, 1990A physiologically based pharmacokinetic model describing the disposition of chloroform in mice, rats, and humans was developed. This model was designed to facilitate extrapolations from high doses, such as those used in chronic rodent studies, to low doses that humans may be exposed to in the workplace or the environment. Kinetic constants for mice and
R A, Corley +7 more
openaire +2 more sources
Development of a Physiologically Based Pharmacokinetic Model for Hydroquinone
Toxicology and Applied Pharmacology, 2000Hydroquinone (HQ) produces nephrotoxicity and renal tubular adenomas in male F344 rats following 2 years of oral dosing. Female F344 and SD rats are comparatively resistant to these effects. Nephrotoxicity and tumorigenicity have been associated with a minor glutathione conjugation pathway following the oxidation of HQ to benzoquinone (BQ).
R A, Corley +4 more
openaire +2 more sources
Physiological-based pharmacokinetic modeling of endotoxin in the rat
Toxicology and Industrial Health, 2012We have previously measured the distribution and pharmacokinetics of biosynthetically radiolabeled endotoxin of Salmonella typhimurium following intraperitoneal (IP) dosing (200 μg/kg) in Sprague-Dawley rats. In our experiments, the fatty acid residues were labeled with 3 H and the ...
Joseph C, Hutter, Chung S, Kim
openaire +2 more sources
A Physiologically Based Pharmacokinetic Model of Inorganic Arsenic
Regulatory Toxicology and Pharmacology, 1999This study presents a physiologically based pharmacokinetic model of inorganic arsenic disposition in humans. The model focuses on short-term exposures by the oral route. The model considers the four circulating species (AsIII, AsV, and two metabolites, i.e., monomethylarsenic (MMA) and dimethylarsenic (DMA)) in tissue groups.
openaire +2 more sources
Physiologically based pharmacokinetic modelling of cefoperazone in paediatrics
British Journal of Clinical PharmacologyAimsCefoperazone is commonly used off‐label in the treatment of bacterial meningitis and sepsis in children, and the pharmacokinetic (PK) data are limited in this vulnerable population. The goal of this study was to develop a physiologically based pharmacokinetic (PBPK) model to predict pediatric cefoperazone exposure for rational dosing ...
Qiushi Wang +4 more
openaire +2 more sources
Physiologically Based Pharmacokinetic Models in Developmental Toxicology
Risk Analysis, 1994The kinetics of disposition of drugs and environmental chemicals will be altered as a result of the rapid and pronounced anatomic and physiologic changes that occur during pregnancy. These include changes in maternal intestinal motility, pulmonary tidal volume and minute volume, cardiac output, and renal function as well as in maternal tissue and fluid
openaire +2 more sources
Physiologically Based Pharmacokinetic Models
1993Jerry N. Blancato, Mahmoud A. Saleh
openaire +1 more source
Physiologically Based Pharmacokinetic Modeling at the Extremes of Age
Clinical Pharmacology & Therapeutics, 2012C, Johnston +3 more
openaire +2 more sources

